PERBANDINGAN EFEK TERAPI PIRASETAM DAN SITIKOLIN TERHADAP PERBAIKAN FUNGSI KOGNITIF PASIEN STROKE ISKEMIK
One of the impacts a stroke is cognitive impairment. Neuroprotector like pirasetam and stikolin is a drugs that can regulate cerebral function by improving the cognitive ability of the brain decreases, but its use is controversial and debated based on scientific research. In several hospitals in Mak...
Saved in:
Main Authors: | , |
---|---|
Format: | Theses and Dissertations NonPeerReviewed |
Published: |
[Yogyakarta] : Universitas Gadjah Mada
2013
|
Subjects: | |
Online Access: | https://repository.ugm.ac.id/123253/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63364 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Gadjah Mada |
Summary: | One of the impacts a stroke is cognitive impairment. Neuroprotector like
pirasetam and stikolin is a drugs that can regulate cerebral function by improving
the cognitive ability of the brain decreases, but its use is controversial and debated
based on scientific research. In several hospitals in Makassar, both of
neuroprotective sitikolin and piresetam widely used in patients with ischemic
stroke. This study aims to determine comparison of therapeutic effects pirasetam
and sitikolin to improved cognitive function ischemic stroke patients seen from
MoCA�s (Montreal Cognitive Assessment) instrument.
This study uses an observational with cohort design. Method of data
collection was done prospectively which patients were grouped in two groups: 35
patients in the pirasetam and 27 patients in the sitikolin. Measuring the
effectiveness pirasetam and sitikolin performed before and after (day 7) therapy
using a scale MoCA. Therapeutic effects pirasetam and sitikolin characterized by
an increase in the value of MoCA.
Analysis of statistic showed that ischemic stroke patients who received
treatment for 7
th
days pirasetam based on total domains showed significant
improvement in cognitive function were 0.000 (p <0.05), but no significant
difference in each domain of cognitive. Ischemic stroke patients who received
sitikolin therapy based on the total domain, showed a significant improvement in
cognitive function is 0.000 (p <0.05) and the domain orientation 0.003 (p <0,05).
There is a significant difference in the domain of conceptual thought in the 7
th day between therapy of pirasetam 0.31±0.631 with sitikolin 0,04±0.192 with a
significance value of 0.033 (p <0.05) and for � MoCA there is not difference
effects between pirasetam and sitikolin to improving cognitive function of patients
with ischemic stroke significance value of 0.217 (p> 0,05). |
---|